Clinical Trial Update: Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis [Phase 2]

View source ↗

Summary

This update reports the Phase 2 clinical trial of Imilecleucel-T (Tcelna) for secondary progressive multiple sclerosis, which has completed the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Progressive Multiple Sclerosis

Drugs mentioned

• Tcelna (Imilecleucel-T)

Snippet

Sponsor: Opexa Therapeutics, Inc. | Conditions: Autoimmune Diseases of the Nervous System, Multiple Sclerosis | Phase 2 | Status: COMPLETED